Windsor Creek Advisors’s ADMA Biologics ADMA Stock Holding History

Windsor Creek Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-82,613	Closed	-$242K	–	169
2020 Q2	$242K	Buy	82,613 +25,000	+43%	+$71.8K	0.08%	137
2020 Q1	$166K	Buy	57,613 +7,613	+15%	+$26.3K	0.06%	146
2019 Q4	$200K	Buy	+50,000	New	+$218K	0.05%	126

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Windsor Creek Advisors's ADMA Position: Q3 2020 in Review

Windsor Creek Advisors sold out of ADMA Biologics (ADMA) in Q3 2020, closing a stake of 82,613 shares — an estimated $242K sold.

Windsor Creek Advisors first reported a position in ADMA in Q4 2019 and held it in 3 quarters. The position peaked at $242K in Q2 2020. 95 funds tracked by Wall St. Rank hold ADMA as of Q3 2020.

Windsor Creek Advisors reported no remaining ADMA Biologics position as of Q3 2020 after selling out during the quarter.
Windsor Creek Advisors sold 82,613 ADMA Biologics shares in Q3 2020, an estimated $242K.
Windsor Creek Advisors first reported a position in ADMA Biologics in Q4 2019 and held it in 3 quarters.
Windsor Creek Advisors's ADMA Biologics position peaked at $242K in Q2 2020.
95 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2020.

Based on Windsor Creek Advisors's 13F filing for Q3 2020, filed 4 Nov 2020.